NEW YORK, June 5, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced the timing for a presentation devoted to its Acute Myeloid Leukemia clinical programs.  The presentation is formally scheduled to be delivered during the "TAT: Targeted Alpha Therapy (TAT) International Symposium" held at the Joint Institute for Computational Sciences in Oak Ridge, TN from 9:15 am to 9:40 am EDT on Wednesday, June 5, 2013.  Dr. Joseph Jurcic, Chief of Leukemia Services at New York Presbyterian/Columbia will deliver the oral presentation of the abstract entitled "Alpha-Particle Immunotherapy for Acute Myeloid Leukemia with Bismuth-213 and Actinium-225."

"Alpha emitters offer the possibility of more efficient leukemia cell killing without the toxicity of intensive chemotherapy," said Dr. Jurcic.  "We are now studying this modality in combination with low-dose chemotherapy in older AML patients for whom new treatments are desperately needed.   The average age for AML patients is 68.  Most of these patients cannot tolerate intensive treatments, and thus their prognosis is extremely poor.  A drug like Actimab-A™ could allow them to avoid the side effects of standard chemotherapy."

Dr. Jurcic's presentation will focus on Actinium Pharmaceuticals' drug candidates Actimab-A™ and Bismab-A™.  In addition to this presentation focusing on Actinium Pharmaceuticals' drug candidates, the symposium will highlight clinical data from a study on the treatment of brain cancer patients with a bismuth-213-based drug candidate and data from an alpha-therapy-based ovarian cancer trial.

About Actimab-A™

Actimab-A™ is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium 225 and bismuth 213.  Antibodies are used as high-precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells.  Actimab-A™ consists of the lintuzumab monoclonal antibody and actinium 225.

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first co-developed by Dr. David Scheinberg at Memorial Sloan-Kettering Cancer Center.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc., based in New York, NY, is a biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or

Contact:
Segio Traversa, CEO
Actinium Pharmaceuticals, Inc.
Email: actimedia@actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr.
Tel:  (203) 258-0159
Email: dsdobson@optonline.com
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.